Invitrocue Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
166.40
705.60
569.80
Cost of Goods Sold (COGS) incl. D&A
-
-
1,209.70
1,504.30
2,095.60
Gross Income
-
-
1,043.30
798.70
1,525.80
SG&A Expense
456.80
1,627.80
1,268.10
1,116.00
3,233.40
EBIT
456.80
1,627.80
2,445.60
1,864.60
4,759.20
Unusual Expense
124.00
1,713.90
19,064.20
-
-
Non Operating Income/Expense
-
152.60
299.70
72.00
307.10
Interest Expense
-
-
698.40
28.50
25.50
Pretax Income
580.80
66.40
21,882.90
1,748.00
4,477.60
Consolidated Net Income
580.80
66.40
21,882.90
1,748.00
4,477.60
Net Income
580.80
66.40
21,882.90
1,748.00
4,477.60
Net Income After Extraordinaries
580.80
66.40
21,882.90
1,748.00
4,477.60
Net Income Available to Common
580.80
66.40
21,882.90
1,748.00
4,477.60
EPS (Basic)
0.00
0.00
0.07
0.00
0.01
Basic Shares Outstanding
140,145.00
15,092.50
300,847.80
444,112.50
472,277.60
EPS (Diluted)
0.00
0.00
0.07
0.00
0.01
Diluted Shares Outstanding
140,145.00
15,477.10
307,749.20
444,112.50
472,277.60
EBITDA
456.80
1,627.80
2,340.20
1,767.40
4,628.10
Other Operating Expense
-
-
134.20
50.00
-
Non-Operating Interest Income
-
-
25.60
3.80
-

About Invitrocue

View Profile
Address
350 Kent Street
Sydney New South Wales (NSW) 2000
Australia
Employees -
Website http://www.invitrocue.com
Updated 07/08/2019
Invitrocue Ltd. provides bio analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. The company focuses on the commercialization of its bio analytics services using cell based model and imaging based technology. Its cell based services enable pharmaceutical and cosmetics companies to refine their drug, ingredient, compound or vaccine discovery efforts and digital pathology business offers solutions, including slide scanning and digitisation; image analytics of tissues and cell samples; pathology consultation with board certified pathologists, and telepathology via an online web-based portal.